×
About 52,068 results

ALLMedicine™ Acute Myeloid Leukemia Center

Research & Reviews  24,653 results

CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered...
https://doi.org/10.1200/EDBK_320085
American Society of Clinical Oncology Educational Book. A... Gill S, Brudno JN

May 14th, 2021 - At the time of writing, five anti-CD19 CAR T-cell products are approved by the U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric B-cell acute lymphoblastic ...

Healthcare resource utilization and economic burden of antifungal management in patient...
https://doi.org/10.1080/03007995.2021.1927691
Current Medical Research and Opinion; Ueno R, Nishimura S et. al.

May 14th, 2021 - To examine treatment patterns of real-world antifungal management of patients at high risk of invasive fungal infections (IFI) and evaluate healthcare resource utilization and costs associated with antifungal management of IFIs in Japan. This retr...

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Series and Review.
https://doi.org/10.1097/DAD.0000000000001968
The American Journal of Dermatopathology; Adnan A, Powell PR et. al.

May 14th, 2021 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy that frequently has cutaneous manifestations. The diagnosis can be a challenge because of its heterogenous clinical presentation, ranging from a b...

Identification and validation of signal recognition particle 14 as a prognostic biomark...
https://doi.org/10.1186/s12920-021-00975-2 10.3390/jcm5030033 10.1053/j.seminhematol.2018.08.001 10.3390/cancers11101440 10.1182/blood-2008-02-134411 10.1056/NEJMoa1301689 10.1093/bioinformatics/btp616 10.1093/nar/gkv007 10.1038/nprot.2008.211 10.1093/bioinformatics/btr260 10.1126/science.1132939 10.1093/nar/gkv1277 10.1515/hsz-2016-0326 10.1111/j.1349-7006.2004.tb03219.x 10.1038/nrc.2016.138 10.3390/cells8010066 10.1080/14728214.2017.1330885 10.1007/s10495-013-0954-z 10.3892/ol.2015.3720 10.1097/PPO.0000000000000378 10.1038/s41591-019-0472-9 10.18632/oncotarget.27086 10.1016/j.leukres.2017.03.011 10.1002/iub.1918 10.1007/s00018-013-1545-4 10.1182/blood-2014-04-569780 10.1182/blood-2017-02-763086 10.1038/leu.2017.116 10.1080/10428194.2016.1266625 10.1016/j.beha.2018.09.010 10.1038/s41467-019-12555-1 10.1016/j.beha.2019.05.004 10.2147/OTT.S156003 10.1002/gcc.22796 10.1038/cddis.2017.317 10.1016/j.celrep.2017.03.018 10.1002/1097-0142(19870501)59:9<1607::AID-CNCR2820590914>3.0.CO;2-3 10.1007/s00520-016-3548-9 10.1007/s00520-017-3904-4 10.1097/00002820-200609000-00012 10.1038/srep44564 10.1158/1535-7163.MCT-14-0469-T 10.1038/bjc.1988.301 10.1038/bjc.1989.215 10.1016/j.bcp.2018.07.013 10.1142/S0219720018500026
BMC Medical Genomics; Shi L, Huang R et. al.

May 14th, 2021 - This study aimed to determine and verify the prognostic value and potential functional mechanism of signal recognition particle 14 (SRP14) in acute myeloid leukemia (AML) using a genome-wide expression profile dataset. We obtained an AML genome-wi...

Selective requirement of MYB for oncogenic hyperactivation of a translocated enhancer i...
https://doi.org/10.1158/2159-8290.CD-20-1793
Cancer Discovery; Smeenk L, Ottema S et. al.

May 13th, 2021 - In acute myeloid leukemia (AML) with inv(3)(q21;q26) or t(3;3)(q21;q26), a translocated GATA2 enhancer drives oncogenic expression of EVI1. We generated an EVI1-GFP AML model and applied an unbiased CRISPR/Cas9 enhancer scan to uncover sequence mo...

see more →

Guidelines  95 results

Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myel...
https://doi.org/10.1016/j.bbmt.2020.09.020
Biology of Blood and Marrow Transplantation : Journal of ... Dholaria B, Savani BN et. al.

Sep 23rd, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML
https://ascopost.com/news/june-2020/ivosidenib-plus-venetoclax-with-or-without-azacitidine-for-idh1-mutated-aml/

May 31st, 2020 - Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML...

AMG 330 Shows Promise in Treating Relapsed/Refractory AML
https://www.onclive.com/conference-coverage/asco-2020/amg-330-shows-promise-in-treating-relapsedrefractory-aml

May 29th, 2020 - Findings showed that AMG 330 was safe and tolerable in treating patients with relapsed or refractory acute myeloid leukemia (AML), with cytokine release syndrome (CRS) as the most frequent and expected adverse event (AE), according to preliminary ...

Palliative Care Improves Quality of Life in Patients With AML
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200172/full/

May 28th, 2020 - When patients with acute myeloid leukemia (AML) undergo intensive chemotherapy treatment, their quality of life (QoL) and mood are negatively affected. Areej El-Jawahri, MD, of Massachusetts General Hospital, presented the results of a multicenter...

High Expression of DOCK2 Indicates Good Prognosis in AML
https://www.jcancer.org/v10p6088.htm
Journal of Cancer; Hu N,et al

Oct 14th, 2019 - DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML).

see more →

Drugs  59 results see all →

Clinicaltrials.gov  25,757 results

CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered...
https://doi.org/10.1200/EDBK_320085
American Society of Clinical Oncology Educational Book. A... Gill S, Brudno JN

May 14th, 2021 - At the time of writing, five anti-CD19 CAR T-cell products are approved by the U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric B-cell acute lymphoblastic ...

Healthcare resource utilization and economic burden of antifungal management in patient...
https://doi.org/10.1080/03007995.2021.1927691
Current Medical Research and Opinion; Ueno R, Nishimura S et. al.

May 14th, 2021 - To examine treatment patterns of real-world antifungal management of patients at high risk of invasive fungal infections (IFI) and evaluate healthcare resource utilization and costs associated with antifungal management of IFIs in Japan. This retr...

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Series and Review.
https://doi.org/10.1097/DAD.0000000000001968
The American Journal of Dermatopathology; Adnan A, Powell PR et. al.

May 14th, 2021 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy that frequently has cutaneous manifestations. The diagnosis can be a challenge because of its heterogenous clinical presentation, ranging from a b...

Identification and validation of signal recognition particle 14 as a prognostic biomark...
https://doi.org/10.1186/s12920-021-00975-2 10.3390/jcm5030033 10.1053/j.seminhematol.2018.08.001 10.3390/cancers11101440 10.1182/blood-2008-02-134411 10.1056/NEJMoa1301689 10.1093/bioinformatics/btp616 10.1093/nar/gkv007 10.1038/nprot.2008.211 10.1093/bioinformatics/btr260 10.1126/science.1132939 10.1093/nar/gkv1277 10.1515/hsz-2016-0326 10.1111/j.1349-7006.2004.tb03219.x 10.1038/nrc.2016.138 10.3390/cells8010066 10.1080/14728214.2017.1330885 10.1007/s10495-013-0954-z 10.3892/ol.2015.3720 10.1097/PPO.0000000000000378 10.1038/s41591-019-0472-9 10.18632/oncotarget.27086 10.1016/j.leukres.2017.03.011 10.1002/iub.1918 10.1007/s00018-013-1545-4 10.1182/blood-2014-04-569780 10.1182/blood-2017-02-763086 10.1038/leu.2017.116 10.1080/10428194.2016.1266625 10.1016/j.beha.2018.09.010 10.1038/s41467-019-12555-1 10.1016/j.beha.2019.05.004 10.2147/OTT.S156003 10.1002/gcc.22796 10.1038/cddis.2017.317 10.1016/j.celrep.2017.03.018 10.1002/1097-0142(19870501)59:9<1607::AID-CNCR2820590914>3.0.CO;2-3 10.1007/s00520-016-3548-9 10.1007/s00520-017-3904-4 10.1097/00002820-200609000-00012 10.1038/srep44564 10.1158/1535-7163.MCT-14-0469-T 10.1038/bjc.1988.301 10.1038/bjc.1989.215 10.1016/j.bcp.2018.07.013 10.1142/S0219720018500026
BMC Medical Genomics; Shi L, Huang R et. al.

May 14th, 2021 - This study aimed to determine and verify the prognostic value and potential functional mechanism of signal recognition particle 14 (SRP14) in acute myeloid leukemia (AML) using a genome-wide expression profile dataset. We obtained an AML genome-wi...

Selective requirement of MYB for oncogenic hyperactivation of a translocated enhancer i...
https://doi.org/10.1158/2159-8290.CD-20-1793
Cancer Discovery; Smeenk L, Ottema S et. al.

May 13th, 2021 - In acute myeloid leukemia (AML) with inv(3)(q21;q26) or t(3;3)(q21;q26), a translocated GATA2 enhancer drives oncogenic expression of EVI1. We generated an EVI1-GFP AML model and applied an unbiased CRISPR/Cas9 enhancer scan to uncover sequence mo...

see more →

News  1,497 results

Fast Five Quiz: Myelodysplastic Syndrome Presentation and Diagnosis
https://reference.medscape.com/viewarticle/950473

May 11th, 2021 - Myelodysplastic syndrome (MDS) is a group of related disorders that arise as the result of distorted hematopoietic stem cell function, inflammatory and innate immune deregulation, and multiple genomic events. These molecular alterations increase t...

Whole-Genome Sequencing Emerging for Routine Cancer Care
https://www.medscape.com/viewarticle/947261

Mar 10th, 2021 - Almost 20 years after the human genome was first mapped, whole-genome sequencing might finally be ready to enter routine cancer care. Researchers at Washington University in St. Louis, St. Louis, Missouri, are commercializing an automated sequenci...

FDA Places Clinical Hold on Sickle Cell Gene Therapy
https://www.medscape.com/viewarticle/946434

Feb 23rd, 2021 - Updated February 25, 2021 // Editor’s note: The original text has been corrected to accurately reflect the status of the patients with AML and MDS. The FDA placed a clinical hold yesterday on two gene therapy trials for sickle cell disease (SCD) a...

Fast Five Quiz: Myelodysplastic Syndrome
https://reference.medscape.com/viewarticle/943967

Jan 27th, 2021 - Myelodysplastic syndrome (MDS) is a group of related hematopoietic disorders characterized by peripheral blood cytopenias, abnormal blood cell development, and clonal genetic markers. Patients with MDS may present with clinical manifestations of a...

Leukemia: New Adverse Event With PARP Inhibitors in Cancer
https://www.medscape.com/viewarticle/943743

Jan 6th, 2021 - A new adverse event has been reported for PARP inhibitor drugs used in the treatment of cancer: the risk of developing myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), both of which have a high mortality rate.   PARP inhibitors are...

see more →

Patient Education  7 results see all →